TTrialPathMatch Me to Trials
← Back to trials
RecruitingCannabis UseMajor Depressive DisorderCognitive Impairment

Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression

Eligible age

18–55 yrs

Accepts

All genders

Locations

0 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.

Sponsor: Centre for Addiction and Mental Health

You may qualify if…

  • ✓ All participants must be between the ages 18-55
  • ✓ Meet SCID for DSM-5 diagnostic criteria for cannabis use disorder, moderate to severe
  • ✓ Meet SCID for DSM-5 diagnostic criteria for Major Depressive Disorder
  • ✓ Be an outpatient receiving a stable dose of antidepressant medication for at least three months (to ensure stability of depressive symptoms
  • ✓ Have a Hamilton Depression Rating Scale (HDRS-17) at baseline assessment in the range of 12-25..
  • ✓ Have a Full-Scale IQ ≥ 80 as determined by the WTAR
  • ✓ Be a non-treatment seeking cannabis user
  • ✓ Evidence of sufficient motivation and effort as measured by a Test of Memory Malingering (TOMM) score ≥ 45.

You may not qualify if…

  • ✕ Meets criteria for substance use disorder of alcohol or other illicit substances within the past 6 months (with the exception of cannabis, nicotine, or caffeine)
  • ✕ Positive urine screen for illicit substances other than cannabis, nicotine, or caffeine
  • ✕ Current suicidal or homicidal ideation
  • ✕ Psychotic disorder diagnosis (e.g. schizoaffective disorder, major depression with psychotic features) as determined by the SCID
  • ✕ Treatment seeking for cannabis use
  • ✕ Meet SCID for DSM-5 diagnostic criteria for Bipolar Disorder
  • ✕ Head Injury\> 5 minutes LOC
  • ✕ Exceed upper and lower cut-offs on HSRD-17 (See Inclusion Criteria)

Source: ClinicalTrials.gov · NCT04935619 · last updated 2025-02-24